These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 18161066)

  • 1. Health economics: basic principles and application in mental health.
    Suh GH
    Int Psychogeriatr; 2007 Dec; 19(6):993-1002. PubMed ID: 18161066
    [No Abstract]   [Full Text] [Related]  

  • 2. [The economic and social costs of dementia].
    Washimi Y; Ohta T
    Nihon Ronen Igakkai Zasshi; 2004 Sep; 41(5):451-9. PubMed ID: 15515718
    [No Abstract]   [Full Text] [Related]  

  • 3. Economic evaluation of cholinesterase inhibitor therapy for dementia: comparison of Alzheimer's disease and Dementia with Lewy bodies.
    Gustavsson A; Van Der Putt R; Jönsson L; McShane R
    Int J Geriatr Psychiatry; 2009 Oct; 24(10):1072-8. PubMed ID: 19639600
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness and cost-effectiveness of the pharmacological treatment of Alzheimer's disease and vascular dementia.
    Versijpt J
    J Alzheimers Dis; 2014; 42 Suppl 3():S19-25. PubMed ID: 25061049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. What explains the diffusion of treatments for mental illness?
    Drake R; Skinner J; Goldman HH
    Am J Psychiatry; 2008 Nov; 165(11):1385-92. PubMed ID: 18981070
    [No Abstract]   [Full Text] [Related]  

  • 6. Modelling the cost effectiveness of cholinesterase inhibitors in the management of mild to moderately severe Alzheimer's disease.
    Bosanquet N; Yeates A
    Pharmacoeconomics; 2006; 24(6):623-5; author reply 625-6. PubMed ID: 16761908
    [No Abstract]   [Full Text] [Related]  

  • 7. Use of FDA approved medications for Alzheimer's disease in mild dementia is associated with reduced informal costs of care.
    Behrens S; Rattinger GB; Schwartz S; Matyi J; Sanders C; DeBerard MS; Lyketsos CG; Tschanz JT
    Int Psychogeriatr; 2018 Oct; 30(10):1499-1507. PubMed ID: 29559029
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pressing issues in the dementias and dementia services.
    Holland M
    Hosp Med; 1999 Jul; 60(7):522-4. PubMed ID: 10605547
    [No Abstract]   [Full Text] [Related]  

  • 9. The use, benefits, and costs of cholinesterase inhibitors for Alzheimer's dementia in long-term care: are the data relevant and available?
    Khang P; Weintraub N; Espinoza RT
    J Am Med Dir Assoc; 2004; 5(4):249-55. PubMed ID: 15228635
    [No Abstract]   [Full Text] [Related]  

  • 10. People with Alzheimer's disease are denied drugs.
    Scott H
    Br J Nurs; 2000 Nov 9-22; 9(20):2120. PubMed ID: 12271179
    [No Abstract]   [Full Text] [Related]  

  • 11. Assessment of health economics in Alzheimer's disease (AHEAD): treatment with galantamine in the UK.
    Ward A; Caro JJ; Getsios D; Ishak K; O'Brien J; Bullock R;
    Int J Geriatr Psychiatry; 2003 Aug; 18(8):740-7. PubMed ID: 12891643
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Economics of dementia and pharmacoeconomics of dementia therapy.
    Fillit H; Hill J
    Am J Geriatr Pharmacother; 2005 Mar; 3(1):39-49. PubMed ID: 16089246
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Issues in the economic evaluation of treatment for dementia. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines.
    Winblad B; Hill S; Beermann B; Post SG; Wimo A
    Alzheimer Dis Assoc Disord; 1997; 11 Suppl 3():39-45. PubMed ID: 9305515
    [No Abstract]   [Full Text] [Related]  

  • 14. Alzheimer's dementia: budget impact and cost-utility analysis of a combination treatment of a cholinesterase inhibitor and memantine in Switzerland.
    Pfeil AM; Kressig RW; Szucs TD
    Swiss Med Wkly; 2012; 142():w13676. PubMed ID: 23180021
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drifting policies are wasting billions.
    Suh GH
    Int Psychogeriatr; 2012 Mar; 24(3):343-5. PubMed ID: 22078134
    [No Abstract]   [Full Text] [Related]  

  • 16. Experts disagree over NICE's approach for assessing drugs.
    Hoey R
    Lancet; 2007 Aug; 370(9588):643-4. PubMed ID: 17726791
    [No Abstract]   [Full Text] [Related]  

  • 17. Opportunities for improving managed care for individuals with dementia: Part 1--The issues.
    Fillit H; Knopman D; Cummings J; Appel F
    Am J Manag Care; 1999 Mar; 5(3):309-15. PubMed ID: 10351027
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Counting costs. Patients will suffer from limits on Alzheimer's drugs.
    Page S
    Nurs Stand; 2005 May 25-31; 19(37):24-5. PubMed ID: 15938410
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mental health services for older adults in the VA system.
    Van Stone WW; Goldstein MZ
    Hosp Community Psychiatry; 1993 Sep; 44(9):828-30. PubMed ID: 8225293
    [No Abstract]   [Full Text] [Related]  

  • 20. Cholinesterase inhibitors in dementia: yes, no, or maybe?
    Lemstra AW; Richard E; van Gool WA
    Age Ageing; 2007 Nov; 36(6):625-7. PubMed ID: 17881419
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.